Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Mustang Bio, Inc.

Mustang Bio, Inc. (“Mustang”) is a clinical-stage bio-pharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.

California Institute for Regenerative Medicine

California Institute of Regenerative Medicine (CIRM)

National Institutes of Health

Runway Growth Capital

Horizon Technology Finance

Mustang Bio

Mustang Bio announces its expansion into #autoimmunediseases with MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the fourth quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more here: https://bit.ly/4azqUGS

Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: https://bit.ly/3Vdj7Kk

Phase 1 clinical data were published in @NatureMedicine that demonstrated the promising safety and clinical activity of Mustang Bio’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO Learn more here:  https://bit.ly/3TeNAVQ


#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. https://bit.ly/3Ij0flf #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO 


#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease. 
 
This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: https://bit.ly/49Ku9KW #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO 

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue				1.37M -	1.78M 30.48%	2.31M 29.19%	3.03M 31.44%	2.23M 26.59%
gross profit				-1.37M -	-1.78M 30.48%	-2.31M 29.19%	-3.03M 31.44%	-2.23M 26.59%
selling and marketing expenses								-365K -
general and administrative expenses	2.82M -	11.41M 305.15%	6.76M 40.76%	9.57M 41.59%	9.51M 0.68%	11.02M 15.91%	12.21M 10.83%	9.69M 20.67%
selling general and administrative expenses	2.82M -	11.41M 305.15%	6.76M 40.76%	9.57M 41.59%	9.51M 0.68%	11.02M 15.91%	12.21M 10.83%	9.32M 23.66%
research and development expenses	8.55M -	20.38M 138.40%	24.46M 20.06%	36.31M 48.44%	47.30M 30.25%	55.71M 17.77%	63.95M 14.80%	39.18M 38.73%
other expenses	6.08M -	12.43M 104.52%	3.36M 72.98%	6.27M 86.70%	10.06M 60.43%	5.84M 41.95%	-1.30M 122.32%
cost and expenses	11.36M -	31.79M 179.72%	31.22M 1.77%	45.88M 46.96%	56.81M 23.80%	66.72M 17.46%	74.86M 12.19%	50.73M 32.23%
operating expenses	11.36M -	31.79M 179.72%	31.22M 1.77%	45.88M 46.96%	56.81M 23.80%	66.72M 17.46%	74.86M 12.19%	48.50M 35.21%
interest expense	1.15M -	8K 99.30%	8K 0%	1.77M 21,987.50%	3.92M 121.68%	15K 99.62%	3.36M 22,293.33%	1.31M 60.88%
ebitda	-11.35M -	-31.28M 175.65%	-30.02M 4.01%	-43.25M 44.06%	-56.10M 29.69%	-66.36M 18.28%	-74.17M 11.77%	-48.50M 34.60%
operating income	11.36M -	-31.79M 379.72%	-31.22M 1.77%	-45.88M 46.96%	-56.81M 23.80%	-66.72M 17.46%	-76.16M 14.14%	-50.73M 33.39%
depreciation and amortization	-22.71M -	2K 100.01%	630K 31,400%	2.63M 317.62%	708K 73.09%	368K 48.02%	1.99M 441.58%	2.23M 11.64%
total other income expenses net	-159K -	497K 412.58%	561K 12.88%	-504K 189.84%	-3.21M 536.71%	353K 111.00%	-1.37M 486.97%	-876K 35.87%
income before tax	-12.65M -	-31.29M 147.26%	-30.66M 2.00%	-46.39M 51.29%	-60.02M 29.37%	-66.37M 10.59%	-77.53M 16.81%	-51.60M 33.44%
income tax expense	23.86M -	505K 97.88%	569K 12.67%	1.77M 210.54%	2.13M 20.66%	-2.29M 207.46%	1.37M 159.62%
net income	-12.65M -	-31.29M 147.26%	-30.66M 2.00%	-48.16M 57.05%	-62.15M 29.05%	-64.08M 3.11%	-78.89M 23.12%	-51.60M 34.59%
weighted average shs out	1.75M -	1.68M 3.73%	1.80M 6.72%	2.40M 33.81%	3.51M 45.83%	5.86M 67.12%	6.90M 17.69%	8.60M 24.78%
weighted average shs out dil	1.75M -	1.68M 3.73%	1.80M 6.72%	2.40M 33.81%	3.51M 45.83%	5.86M 67.12%	6.90M 17.69%	8.60M 24.78%
eps	-7.24 -	-18.58 156.63%	-17.07 8.13%	-20.03 17.34%	-17.73 11.48%	-10.94 38.30%	-11.44 4.57%	-6 47.55%
epsdiluted	-7.24 -	-18.58 156.63%	-17.07 8.13%	-20.03 17.34%	-17.73 11.48%	-10.94 38.30%	-11.44 4.57%	-6 47.55%

NASDAQ:MBIO

Mustang Bio

Last Close

0.30

17/05 20:00

Market Cap

14.39M

Beta: 1.86

Volume Today

178.67K

Avg: 49.10K

PE Ratio

−0.16

PFCF: −0.23